MinervaX minervax.com


MinervaX is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity.

MinervaX is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity.

Company (Alive / Active)

Phone:

Fax:

Ole Maaloes Vej 3

Copenhagen, 2200
Denmark

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
MinervaX $4.1M Jan 8, 2014

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related MinervaX Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Novo HoldingsHolding CompanyHellerup, Denmark
Sunstone CapitalVenture CapitalCopenhagen, DenmarkSeed VC
LF InvestmentsCorporate VentureHellerup, DenmarkSeed VC
Novo SeedsCorporate VentureHellerup, DenmarkSeed VC
See all 6 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Fusion protein vaccine Apr 14, 2008 Nov 20, 2012 Patent